Amneal Pharmaceuticals (AMRX) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Amneal Pharmaceuticals (AMRX) do?
Amneal Pharmaceuticals Inc (AMRX) is a U.S.-listed company in Healthcare (Drug Manufacturers - Specialty & Generic). What it does: Develops, manufactures, and sells generic and branded prescription pharmaceuticals across multiple dosage formats. Manufactures complex generic, biosimilar, and specialty drugs across proprietary facilities in the US and India. It is worth $7.45B on the market and sold $3.20B over the last year.
- Market cap
- $7.45B
- P/E ratio
- 52.5×
- Annual sales
- $3.20B
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Brief updated
- Nov 13, 2026
Brands and businesses behind AMRX
- Rytary: Generates revenue from prescription sales to treat Parkinson disease symptoms in adult patients.
- Crexont: Earns revenue from prescription sales of extended release carbidopa and levodopa for Parkinson disease management.
- Unithroid: Generates sales as a daily branded prescription tablet for patients with hypothyroidism.
- Emverm: Earns revenue from chewable prescription tablets prescribed to treat systemic pinworm and roundworm infections.
AMRX’s flags, in plain English
Each flag is a number from Amneal Pharmaceuticals’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 13, 2026.
Insiders Hold
Insiders own 55% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.
Growth vs Price
The price looks reasonable for how fast it is growing. The price looks reasonable for how fast its profits are growing.
Stupid Cash
Can pay this year's bills 1.9 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Debt Is Driving
Heavy debt, 618% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.
2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.
Questions about AMRX
How big is Amneal Pharmaceuticals?
Amneal Pharmaceuticals’ market cap is $7.45B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $3.20B: what customers paid the company over the last year, before any costs.
What is AMRX’s P/E ratio?
AMRX’s P/E ratio is 52.5×. Investors pay about 52.5 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with AMRX?
Heavy debt of over two billion dollars creates substantial interest expense and limits capital allocation flexibility. That is one risk on Amneal Pharmaceuticals’ card. Its first risk flag is Debt Is Driving, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Amneal Pharmaceuticals’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. AMRX’s filings on SEC.gov. The Margin Monkey is research, not advice.
